Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord blood mononuclear cell gel is a cell therapy product consisting of mononuclear cells (MNCs) isolated from human umbilical cord blood and formulated into a gel for topical application. It is primarily being investigated for the treatment of refractory diabetic foot ulcers (DFU). The therapeutic mechanism involves the paracrine secretion of various growth factors and cytokines by the MNCs, which helps to restore the local repair microenvironment, promote angiogenesis, and accelerate wound healing. In clinical research, it is often evaluated in combination with platelet-rich plasma (PRP) to enhance its regenerative effects by providing a scaffold and additional growth factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord blood mononuclear cell gel.